RAGE expression in the human peritoneal membrane

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3302-3306

  Kihm, Lars P ^a   Wibisono, Dennis ^a   Müller Krebs, Sandra ^a   Pfisterer, Friederike ^a   Morath, Christian ^a   Gross, Marie L ^a   Morcos, Michael ^a   Seregin, Yuri ^a   Bierhaus, Angelika ^a   Nawroth, Peter P ^a   Zeier, Martin ^a   Schwenger, Vedat ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AGE; Peritoneal damage; Peritoneum; RAGE

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 6; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE; RAGE ENZYME; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CATHETER REMOVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY FIBROSIS; MALE; PERITONEAL BIOPSY; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; UREMIA;

CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PERITONEAL DIALYSIS; PERITONEUM; RECEPTORS, IMMUNOLOGIC; UREMIA;

EID: 52449103821     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn272     Document Type: Article

References (19)

1. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186
2. Yan SF, Ramasamy R, Naka Y et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169
3. De Vriese AS, Flyvbjerg A, Mortier S et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14: 2109-2118
4. De Vriese AS, Tilton RG, Mortier S et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21: 2549-2555
5. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207
6. Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808
7. Schmidt AM, Hori O, Cao R et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45(Suppl 3): S77-S80
8. Lu M, Kuroki M, Amano S et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-1224
9. Boulanger E, Wautier MP, Wautier JL et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-156
10. Ogata S, Yorioka N, Nishida Y et al. Expression of receptor for advanced glycation end product mRNA by human peritoneal mesothelial cells. Nephron 2000; 86: 245-246
11. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-822
12. Inagi R, Miyata T, Yamamoto T et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260-264
13. Schmidt AM, Yan SD, Wautier JL et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497
14. Wendt T, Bucciarelli L, Qu W et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002; 4: 228-237
15. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265
16. Zareie M, Fabbrini P, Hekking LH et al. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. J Am Soc Nephrol 2006; 17: 3447-3457
17. Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863
18. Powell DW, Mifflin RC, Valentich JD et al. Myofibroblasts: II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277: C183-201
19. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413